NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Jun 27, 2016) - Avita Medical's autologous skin healing technology shows strong effectiveness in treating burns, chronic wounds and aesthetics, and will help strained public health budgets, according to a comprehensive review of data presented at a scientific symposium by a leading Regenerative Medicine journal, the Company said today.
Avita Medical Limited (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, ran the 4th Skin Regeneration Symposium (SRS) in Cambridge, UK in April 2016. Data from the event, presented by leading clinicians worldwide to the some 140 attendees, has now been published on RegMedNet.com, which is the online platform for peer-reviewed journal Regenerative Medicine.
The full three-part review together with clinician interviews are published with free access at Regenerative Medicine.
-
Part 1 covers the REPAIR session of the Symposium, focused on ReCell®, Avita's proprietary technology for the treatment of burns
-
Part 2, on the RESTART session which concentrated on ReGenerCell™, Avita's chronic wounds device that is used to treat long standing wounds such as Venous Leg Ulcers and Diabetic Foot Ulcers
-
Part 3 concludes with the RESTORE session which looked at the use of ReNovaCell™, Avita's device which covers aesthetic applications including vitiligo and scarring
During the Symposium, Regenerative Medicine interviewed leading clinicians about their experience pioneering Avita Medical's autologous skin healing technology based on its RES™ -- Regenerative Epithelial Suspension -- technology that uses just a small sample of the patient's skin. The experts had all presented strong clinical results in their various areas of expertise, and agreed that a call for action is now needed to move Avita's medical devices into mainstream medical practice, to improve lives of patients, whilst saving healthcare costs.
"This versatile technology could be used in a number of ways in the same patient without an incremental increase in cost, since length of stay can be reduced so dramatically," said Dr James H. Holmes IV, Wake Forest University School of Medicine. "That can have a huge impact on the healthcare system and society as a whole, since the patient is able to return to a functional state more quickly: whether that's going back to work, or driving a car."
His views were shared by Mr Paul Hayes, Vascular Surgeon at Addenbrooke's Hospital, who explained that VLUs consume 10-20% of vascular surgery clinic time, while great resources were also being spent on treating Britain's some 100,000 DFU patients1. Mr Hayes said it was much cheaper to treat patients as an out-patient, which was one of the attractions to ReGenerCell™.